Newsroom | 5074 results
Sorted by: Latest
-
Median Technologies to Host Webcasts Highlighting Strategic Advances Driving U.S. Deployment of eyonis® LCS
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as Medical Devices (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that it will host two webcasts on February 26, 2026. The webcasts, titled “Transforming Lung Cancer Sc...
-
QT Imaging Achieves Major Reimbursement Milestone with AMA Category III CPT Code for 3D Breast Ultrasound Tomography
NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that the American Medical Association (AMA) CPT (Current Procedural Terminology) Editorial Panel has approved a new Category III CPTTM code for 3D quantitative transmission volumetric ultrasound tomography of the breast. The new Category III code...
-
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
SAN ANTONIO, Texas--(BUSINESS WIRE)--In new case study, CyPath Lung spares elderly woman from an invasive procedure for a suspicious lung nodule discovered on a CT scan....
-
GE HealthCare achieves MRI portfolio milestone with FDA clearances for next-generation SIGNA MRI technology designed to enhance precision imaging and clinical efficiency
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today 510(k) clearance of three new magnetic resonance (MR) innovations with the U.S. Food and Drug Administration (FDA): SIGNA™ Sprint with Freelium™1, a 1.5T sealed magnet MRI system; SIGNA™ Bolt2, an advanced 3T MRI scanner; and SIGNA™ One3, an AI-driven ecosystem of workflow solutions designed to help reduce inefficiencies and support MRI exams from plan to scan and beyond. The new MRI systems and technology combat some of the...
-
FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a provider of AI-enhanced and central imaging services for oncology drug developers, today announced the appointment of Oran Muduroglu as President of Median eyonis Inc., Median’s U.S. subsidiary. Oran will lead the U.S. launch and...
-
Ibex Medical Analytics Accelerates Global Momentum in AI-Powered Pathology with Strategic Leadership Transition and Expansion in Biopharma
BOSTON & TEL AVIV, Israel--(BUSINESS WIRE)--Ibex Medical Analytics (Ibex), the global leader in clinical-grade AI-powered pathology, today announced continued commercial momentum and expanding global adoption alongside a leadership transition designed to accelerate the company’s next phase of growth. Effective immediately, Yair Heller, formerly Chief Operating Officer, has been appointed Chief Executive Officer, and co-founder Joseph Mossel will lead Ibex’s rapidly expanding biopharma division...
-
Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the launch of Sensus Healthcare Financial Services, a new program intended to make it easier for dermatology practices to acquire Sensus’ superficial radiotherapy (SRT) systems through a streamlined process and flexible financing structure...
-
A Life Spine anuncia status de compatibilidade com ressonância magnética para as linhas de produtos do sistema de espaçador expansível ProLift
HUNTLEY, Illinois--(BUSINESS WIRE)--A Life Spine, empresa de dispositivos médicos que projeta, desenvolve, fabrica e comercializa produtos para o tratamento cirúrgico de distúrbios da coluna vertebral, anunciou hoje que seu portfólio de espaçadores intercorporais expansíveis ProLift® foi avaliado e confirmado como compatível com ressonância magnética, de acordo com os padrões da ASTM. O status de compatibilidade com ressonância magnética inclui o ProLift, o ProLift Micro e o ProLift Lateral, pr...
-
Life Spine anuncia que sus líneas de productos del sistema espaciador expandible ProLift obtienen la certificación de Condicional para RM
HUNTLEY, Illinois--(BUSINESS WIRE)--Life Spine, una empresa especializada en dispositivos médicos que diseña, desarrolla, fabrica y comercializa productos para el tratamiento quirúrgico de trastornos de la columna vertebral, anuncia que su gama de implantes intervertebrales expandibles ProLift® ha sido evaluada y confirmada como Condicional para Resonancia Magnética de acuerdo con las normas ASTM. La clasificación de Condicional para RM incluye a los productos ProLift, ProLift Micro y ProLift L...
-
Life Spine Announces MR Conditional Status for ProLift Expandable Spacer System Product Lines
HUNTLEY, Ill.--(BUSINESS WIRE)--Life Spine, a medical device company that designs, develops, manufactures, and markets products for the surgical treatment of spinal disorders, announced today its ProLift® expandable interbody portfolio has been evaluated and confirmed as MR Conditional in accordance with ASTM standards. The MR Conditional status includes ProLift, ProLift Micro, and ProLift Lateral, which are designed to support interbody fusion procedures across TLIF, PLIF, and LLIF. The MR Con...
